Market revenue in 2023 | USD 127.6 million |
Market revenue in 2030 | USD 312.2 million |
Growth rate | 13.6% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.83% in 2023. Horizon Databook has segmented the Japan hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most technologically advanced countries in Asia Pacific. Its hereditary angioedema therapeutics market is expected to grow rapidly over the forecast period owing to high government spending to reduce the disease burden.
HAE is estimated to affect 1 in 10,000 to 1 in 50,000 people worldwide. There are approximately 2500 HAE patients in Japan, but only 450 have been reported as of 2018, implying that there may be many patients with undiagnosed HAE.
Moreover, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the country's market. In March 2023, Takeda announced the Ministry of Health, Labour and Welfare (MHLW) approval for TAKHZYRO (lanadelumab), a prophylactic solution against acute HAE attacks in Japan.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account